These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 18324957

  • 21. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice.
    Schreiber SA, Russmann A.
    Curr Med Res Opin; 2006 Feb; 22(2):335-41. PubMed ID: 16466605
    [Abstract] [Full Text] [Related]

  • 22. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 23. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M, Pinget M, Gin H, Thivolet C, Hanaire H, Robert JJ, Fontaine P.
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [Abstract] [Full Text] [Related]

  • 24. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes.
    Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM, BIAsp-3021 study group.
    Diabetes Obes Metab; 2007 Sep; 9(5):724-32. PubMed ID: 17593237
    [Abstract] [Full Text] [Related]

  • 25. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 26. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

  • 27. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

  • 28. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 29. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 30. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH, Nattrass M, Pieber TR.
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [Abstract] [Full Text] [Related]

  • 31. Long-term glycaemic control with insulin glargine in Type 2 diabetes.
    Kacerovsky-Bielesz G, Dressler A, Freunscht R.
    Diabetes Res Clin Pract; 2006 Feb; 71(2):184-91. PubMed ID: 16112241
    [Abstract] [Full Text] [Related]

  • 32. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice.
    Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I.
    Diabetes Res Clin Pract; 2010 May; 88 Suppl 1():S11-6. PubMed ID: 20466163
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus.
    Singh KP, Periyandavar I, Rajadhyaksha GC, Jayaram S, Mishra AB, Kinagi S, Sharma A, Baliga VP.
    J Indian Med Assoc; 2007 Jun; 105(6):344, 346, 350. PubMed ID: 18232183
    [Abstract] [Full Text] [Related]

  • 34. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
    Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2007 May; 9(3):428-34. PubMed ID: 17391171
    [Abstract] [Full Text] [Related]

  • 35. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
    Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI.
    Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
    [Abstract] [Full Text] [Related]

  • 36. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Marks JB.
    Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):490-1. PubMed ID: 18594486
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus.
    Kawamori R, Eliaschewitz FG, Takayama H, Hayashida CY.
    Diabetes Res Clin Pract; 2008 Jan; 79(1):97-102. PubMed ID: 17919763
    [Abstract] [Full Text] [Related]

  • 38. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S, Maran A, Mannino D, Morano S, Lastoria G, Nicoziani P.
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [Abstract] [Full Text] [Related]

  • 39. Study design and baseline characteristics of patients in the PRESENT study.
    Shestakova M, Bech OM, Momani MS.
    Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S3-9. PubMed ID: 18672309
    [Abstract] [Full Text] [Related]

  • 40. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.